Is this the buy-the-dip opportunity investors have been waiting for? In this video, I will be going over TransMedics Group's (TMDX 0.85%) third-quarter earnings report. Watch the short video to learn more, consider subscribing, and click the special offer link below. *Stock prices used were from the trading day of Oct. 29, 2024. The video was published on Oct. 29, 2024. ...

SAN DIEGO, Oct. 28, 2024 (GLOBE NEWSWIRE) -- DiCello Levitt LLP announces that it is investigating whether TransMedics Group, Inc. ("TransMedics" or the "Company") (NASDAQ:TMDX) complied with federal securities laws. The Firm's investigation focuses on whether the Company violated the federal securities laws, issued false and/or misleading statements, and/or failed to disclose information required to be disclosed to investors. Investors who purchased TransMedics securities and those with information about t ...

TransMedics Group, Inc. (NASDAQ:TMDX) Q3 2024 Earnings Conference Call October 28, 2024 4:30 PM ET Company Participants Laine Morgan - Gilmartin Group, Investor Relations Waleed Hassanein - President and Chief Executive Officer Stephen Gordon - Chief Financial Officer Conference Call Participants Allen Gong - JPMorgan William Plovanic - Canaccord Joshua Jennings - TD Cowen Ryan Daniels - William Blair Matthew O'Brien - Piper Sandler Suraj Kalia - Oppenheimer & Company David Rescott - Baird Mike Matson - Nee ...

TransMedics (TMDX) came out with quarterly earnings of $0.12 per share, missing the Zacks Consensus Estimate of $0.28 per share. This compares to loss of $0.12 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -57.14%. A quarter ago, it was expected that this medical technology company would post earnings of $0.21 per share when it actually produced earnings of $0.35, delivering a surprise of 66.67%.Over the last four quarters, ...

Exhibit 99.1 TransMedics Reports Third Quarter 2024 Financial Results Andover, Mass. – October 28, 2024 – TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended September 30, 2024. Recent Highlights ▪ Total revenue of $108.8 million in the third quarter of 2024, a 64% increase compared to the third quarter of 2023 ▪ Gen ...

ANDOVER, Mass., Oct. 28, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended September 30, 2024. Recent Highlights Total revenue of $108.8 million in the third quarter of 2024, a 64% increase compared to the third quarter of 2023 Generated net income of $4.2 million or $0.12 per diluted share in ...

Analysts on Wall Street project that TransMedics (TMDX) will announce quarterly earnings of $0.28 per share in its forthcoming report, representing an increase of 333.3% year over year. Revenues are projected to reach $114.22 million, increasing 71.9% from the same quarter last year.The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.Prior to a co ...

TransMedics Group (TMDX) is scheduled to report third-quarter 2024 results on Oct. 28, after market close.In the last reported quarter, the company’s adjusted earnings per share of 35 cents surpassed the Zacks Consensus Estimate by 66.7%. Earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 287.5%.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.TMDX’s Q3 EstimatesThe Zacks Consensus Estimate for revenues is pegged at $114.2 million, imp ...

Wall Street expects a year-over-year increase in earnings on higher revenues when TransMedics (TMDX) reports results for the quarter ended September 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on October 2 ...

I first became aware of TransMedics Group, Inc. (NASDAQ: TMDX ) through social media earlier this year and purchased my first shares in April of this year. While this was a very small My primary area of concentration will be on identifying companies of exceptional caliber, with a proven ability to reinvest capital for impressive returns. Targeting those with a market capitalization of less than $10 billion, affords ample opportunities for growth. The ideal scenario is for these companies to demonstrate a lo ...